Understanding Generalised Pustular Psoriasis: Chronicity, Diversity, Heterogeneity, and Beyond Physical Symptoms

This content was funded by Boehringer Ingelheim International GmbH and is intended for HCPs outside of UK, US and Japan.

The Chronic Nature of Generalised Pustular Psoriasis

This video from Boehringer Ingelheim focuses on the chronic nature of generalised pustular psoriasis (GPP)¹. It features insights from Tiago Torres and Joel Gelfand, who discuss the persistent and relapsing nature of GPP, its symptoms, and its impact on patient’s quality of life^1,2. They emphasise the importance of managing GPP as a chronic condition to alleviate symptoms and improve patient’s well-being¹. The video highlights the physical, emotional, and social challenges faced by patients with GPP^2,3 and the need for effective treatment to prevent severe flares and hospitalisations¹.

Heterogeneity of Generalised Pustular Psoriasis

This video from Boehringer Ingelheim explores the heterogeneity of GPP¹. Torres and Gelfand explain that GPP is highly variable and unpredictable, both between different patients, and within the same patient over time¹. They discuss how symptoms can range from mild to severe and how the unpredictable nature of the disease can significantly impact patient’s quality of life^1,2. The video highlights the challenges in managing GPP due to its variability, and the psychological burden it places on patients, emphasising the need for effective and rapid treatments to help patients maintain a normal life^1,2.

The Impact of Generalised Pustular Psoriasis Beyond Physical Symptoms

This video from Boehringer Ingelheim discusses the impact of GPP beyond physical symptoms. Torres and Gelfand explain that GPP is characterised by persistent disease with relapsing flares, leading to significant physical, mental, and social impacts^1-3. They highlight the stigmatisation and emotional distress caused by visible symptoms², the financial burden of treatments and hospitalisations³, and the crucial role of caregivers⁴. The video emphasises the importance of managing GPP as a chronic condition to improve patient’s quality of life and alleviate the overall burden of the disease¹.

Thumbnail Image: Burns M et al. New onset generalized pustular psoriasis rapidly improved with IL-36 blockade. SKIN J Cutaneous Med. 2023;7(1):585-8.

References

1. Rivera-Diaz R et al. Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment. Dermatol Ther (Heidelb). 2023;13:673-88.
2. Reisner DV et al. Impact of generalized pustular psoriasis from the perspective of people living with the condition: results of an online survey. Am J Clin Dermatol. 2022;23(Suppl 1):65-71.
3. Kharawala S et al. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239-52.
4. Act4GPP. GPP community – hear from people living with GPP. Available at: https://www.act4gpp.com/en/gpp-community. 2022. Last accessed: 15 November 2024.

1. Director at the Psoriasis and Phototherapy Treatment Center, University of Pennsylvania, USA.
2. Professor of Dermatology, Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Portugal.

PC-CRP-105121 November 2024